Skip main navigation

Military Health System

Clear Your Browser Cache

This website has recently undergone changes. Users finding unexpected concerns may care to clear their browser's cache to ensure a seamless experience.

Skip subpage navigation

DOD P&T Committee: 2015 Meetings

In the event the class of drugs specified herein has previously been reviewed, the government solicits quotes for new Blanket Purchase Agreements (BPAs)/Voluntary Agreement for Retail Refunds (VARRs) to replace any existing BPAs/VARRs. The government will not consider existing BPA/VARR prices in the Uniform Formulary (UF) evaluation. Any existing BPA/VARR for this class of drugs will be terminated upon the conclusion of the UF decision.

Meeting Date  Review Type  Drug Classes/New Drugs Under Review/Information for Manufacturers  Meeting Window for Manufacturers to give Clinical/Cost Presentation 

February 2015

Class Review Oral Oncological Agents/Prostate I & II

December 2014

Belsomra - Solicitation Cancelled



Class Review Transmucosal Immediate Rlease Fentanyl
Class Review Pulmonary Aterial Hypertension Agents
Designated Newly Approved Drugs  Zonitivity, Hetlioz, Belsomra, Jardiance, Esomeprasole Strontium, Stendra 

May 2015

Class Review Newer Oral Anticoagulants and Warfarin March 2015
Class Review  Hepatitis Antivirals (Hepatitis C)
Designated Newly Approved Drugs Belsomra, Plegridy, Diclegis
August 2015 Class Review Diabetes Non-Insulin (GLP-1 Receptor Agonists) June 2015
Class Review  Diabetes Non-Insulin (SGLT-2 Inhibitors)
Class Review Narcotic Analgesics - Long Acting
Class Review Oncological Agents - CML Drugs
Designated Newly Approved Drugs  Incruse Ellipta, Cosentyx
November 2015 Class Review Attention Deficit Hyperactivity Disorder - Stimulants

October 2015

Class Review  Antirheumatics - Injectable Methorexate 
Class Review  Gastrointestinal-2 Agents - Miscellaneous
Class Reveiw  Acne - Isotretinoids 
Designated Newly Approved Drugs  Namenda XR, Namzaric

Subject to Change Disclaimer

The Defense Health Agency (DHA) reserves the right to change the classes, sub-classes and/or designated new drugs, and other requirements, of whatever kind, affecting solicitations. The provisions of this table do not constitute a contract, express or implied, between the DHA and manufacturer or eligible bidder.

If the DoD P&T Committee is unable to complete an evaluation of any of the drug classes, the Committee will continue its efforts at the next meeting.

Last Updated: April 25, 2024
Follow us on Instagram Follow us on LinkedIn Follow us on Facebook Follow us on X Follow us on YouTube Sign up on GovDelivery